Altimmune Inc Asset Resilience Ratio
Altimmune Inc asset resilience ratio. Altimmune Inc (ALT) has an Asset Resilience Ratio of 82.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Altimmune Inc (ALT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Altimmune Inc (2007–2025)
Asset resilience ratio of Altimmune Inc from 2007 to 2025. This chart shows how Altimmune Inc's Asset Resilience Ratio has changed over time. Read ALT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Altimmune Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALT asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.70 Million | 82.06% |
| Total Liquid Assets | $229.70 Million | 82.06% |
Asset Resilience Insights
- Very High Liquidity: Altimmune Inc maintains exceptional liquid asset reserves at 82.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Altimmune Inc Industry Peers by Asset Resilience Ratio
Compare Altimmune Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Altimmune Inc Asset Resilience Ratio by Year (2007–2025)
Altimmune Inc asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Altimmune Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.06% | $229.70 Million | $279.93 Million | +13.89pp |
| 2024-12-31 | 68.17% | $94.97 Million | $139.31 Million | +38.40pp |
| 2023-12-31 | 29.77% | $62.70 Million | $210.64 Million | -5.89pp |
| 2022-12-31 | 35.66% | $73.78 Million | $206.93 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $218.86 Million | -- |
| 2020-12-31 | 40.80% | $100.01 Million | $245.12 Million | -11.51pp |
| 2019-12-31 | 52.31% | $28.28 Million | $54.06 Million | +46.70pp |
| 2017-12-31 | 5.61% | $3.53 Million | $63.03 Million | -24.12pp |
| 2016-12-31 | 29.73% | $66.81 Million | $224.74 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $19.86 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $21.98 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $22.80 Million | -- |
| 2009-12-31 | 9.21% | $3.14 Million | $34.07 Million | +3.55pp |
| 2008-12-31 | 5.66% | $3.19 Million | $56.39 Million | -12.59pp |
| 2007-12-31 | 18.25% | $12.15 Million | $66.61 Million | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.